109 related articles for article (PubMed ID: 27354381)
1. Immuno-PET Imaging of Engineered Human T Cells in Tumors.
Mall S; Yusufi N; Wagner R; Klar R; Bianchi H; Steiger K; Straub M; Audehm S; Laitinen I; Aichler M; Peschel C; Ziegler S; Mustafa M; Schwaiger M; D'Alessandria C; Krackhardt AM
Cancer Res; 2016 Jul; 76(14):4113-23. PubMed ID: 27354381
[TBL] [Abstract][Full Text] [Related]
2. In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET.
Yusufi N; Mall S; Bianchi HO; Steiger K; Reder S; Klar R; Audehm S; Mustafa M; Nekolla S; Peschel C; Schwaiger M; Krackhardt AM; D'Alessandria C
Theranostics; 2017; 7(9):2402-2416. PubMed ID: 28744323
[TBL] [Abstract][Full Text] [Related]
3. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
[TBL] [Abstract][Full Text] [Related]
4. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
5. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.
McCracken MN; Vatakis DN; Dixit D; McLaughlin J; Zack JA; Witte ON
J Clin Invest; 2015 May; 125(5):1815-26. PubMed ID: 25822024
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
9. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
10. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Tavaré R; Escuin-Ordinas H; Mok S; McCracken MN; Zettlitz KA; Salazar FB; Witte ON; Ribas A; Wu AM
Cancer Res; 2016 Jan; 76(1):73-82. PubMed ID: 26573799
[TBL] [Abstract][Full Text] [Related]
11. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
14. Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.
Tavaré R; McCracken MN; Zettlitz KA; Salazar FB; Olafsen T; Witte ON; Wu AM
J Nucl Med; 2015 Aug; 56(8):1258-64. PubMed ID: 25952734
[TBL] [Abstract][Full Text] [Related]
15. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
16. Advances in PET Detection of the Antitumor T Cell Response.
McCracken MN; Tavaré R; Witte ON; Wu AM
Adv Immunol; 2016; 131():187-231. PubMed ID: 27235684
[TBL] [Abstract][Full Text] [Related]
17. 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET.
Griessinger CM; Maurer A; Kesenheimer C; Kehlbach R; Reischl G; Ehrlichmann W; Bukala D; Harant M; Cay F; Brück J; Nordin R; Kohlhofer U; Rammensee HG; Quintanilla-Martinez L; Schaller M; Röcken M; Pichler BJ; Kneilling M
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1161-6. PubMed ID: 25587131
[TBL] [Abstract][Full Text] [Related]
18. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.
Ochi T; Fujiwara H; Yasukawa M
Expert Opin Biol Ther; 2011 Jun; 11(6):699-713. PubMed ID: 21413911
[TBL] [Abstract][Full Text] [Related]
19. Designer T cells by T cell receptor replacement.
Sommermeyer D; Neudorfer J; Weinhold M; Leisegang M; Engels B; Noessner E; Heemskerk MH; Charo J; Schendel DJ; Blankenstein T; Bernhard H; Uckert W
Eur J Immunol; 2006 Nov; 36(11):3052-9. PubMed ID: 17051621
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
